` CHM (Chimeric Therapeutics Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

CHM
vs
S&P/ASX 300

Over the past 12 months, CHM has underperformed S&P/ASX 300, delivering a return of -78% compared to the S&P/ASX 300's 10% growth.

Stocks Performance
CHM vs S&P/ASX 300

Loading
CHM
S&P/ASX 300
Add Stock
www.alphaspread.com

Performance Gap
CHM vs S&P/ASX 300

Performance Gap Between CHM and AXKO
HIDDEN
Show

Performance By Year
CHM vs S&P/ASX 300

Loading
CHM
S&P/ASX 300
Add Stock

Competitors Performance
Chimeric Therapeutics Ltd vs Peers

S&P/ASX 300
CHM
ABBV
AMGN
GILD
VRTX
Add Stock

Chimeric Therapeutics Ltd
Glance View

Market Cap
7.4m AUD
Industry
Biotechnology

Chimeric Therapeutics Ltd. develops Chlorotixin CAR-T technology based cell therapies for the curation of solid tumors. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-01-18. The firm's technology known as CLTX-CAR T, uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. The CAR T cell is an immune T cell taken from a patient’s blood which is sent to a lab where it is re-programmed to become a charged guided missile, to seek out a specific target on the surface of a cancer cell.

CHM Intrinsic Value
HIDDEN
Show
Back to Top